Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab in Discussions with Global BioPharmas for a Deal

publication date: Oct 6, 2021

According to a Bloomberg article, I-Mab is in wide-ranging discussions with US and EU biopharmas for a deal that could out-license an I-Mab asset or involve a direct investment in the Shanghai biopharma. The potential investors were not named. One year ago, I-Mab announced a blockbuster $2 billion deal with AbbVie for global ex-China rights to I-Mab's anti-CD47 mAb. The agreement included options on two other anti-CD47 molecules for another billion dollars. Simultaneously, I-Mab is planning a second IPO on Shanghai's STAR board. More details....

Stock Symbols: (NSDQ: IMAB) (NYSE: ABBV)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.